Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma

Hepatology. 2019 Aug;70(2):745-747. doi: 10.1002/hep.30588. Epub 2019 Apr 11.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiopoietin-2 / antagonists & inhibitors*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / pathology
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / pathology
  • Male
  • Middle Aged
  • Phenylurea Compounds / pharmacology*
  • Phenylurea Compounds / therapeutic use*
  • Pyridines / pharmacology*
  • Pyridines / therapeutic use*
  • Receptor, TIE-2 / antagonists & inhibitors*
  • Treatment Outcome

Substances

  • ANGPT2 protein, human
  • Angiopoietin-2
  • Phenylurea Compounds
  • Pyridines
  • regorafenib
  • Receptor, TIE-2